REGN/SNY—John LaMattina (who should know about these things) estimates that the 18,000-patient phase-3 trial of REGN727, called ODYSSEY OUTCOMES, will cost $500M (!) to conduct: http://www.forbes.com/sites/johnlamattina/2012/11/06/will-sanofi-regeneron-ride-odyssey-into-riches/